Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference
Turn Therapeutics Inc. (TTRX)
Company Research
Source: Business Wire
Phase 2 trial of GX-03 for moderate-severe atopic dermatitis on track to complete both interim analysis and topline data in first half of 2026Appointment of Martin Dewhurst, a 30+ years McKinsey & Company M&A veteran, strengthens Company board of directorsExpansion of intranasal vaccine pipeline to include intranasal Influenza candidate that may stimulate systemic immunity via targeted intranasal exposure without adjuvants or potentially harmful additivesProgress on commercial partnerships with expected revenue generation in 2026 in advanced wound care market LOS ANGELES--(BUSINESS WIRE)--Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunological therapies for dermatologic and infectious diseases, today announced corporate, financial, and pipeline updates in advance of its participation at the 2026 J.P. Morgan Healthcare Conference, taking place January 12–15, 2026, in San Francisco. Throughout the conference, T
Show less
Read more
Impact Snapshot
Event Time:
TTRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TTRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TTRX alerts
High impacting Turn Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
TTRX
News
- Turn Therapeutics Appoints Martin Dewhurst to its Board of DirectorsGlobeNewswire
- Turn Therapeutics (NASDAQ:TTRX) is now covered by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>. They set a "sell (e-)" rating on the stock.MarketBeat
- Turn Therapeutics (NASDAQ:TTRX) was upgraded by analysts at D Boral Capital to a "strong-buy" rating.MarketBeat
- Turn Therapeutics (NASDAQ:TTRX) was upgraded by analysts at D Boral Capital to a "strong-buy" rating.MarketBeat
- Turn Therapeutics (NASDAQ:TTRX) is now covered by analysts at D. Boral Capital. They set a "buy" rating and a $8.00 price target on the stock.MarketBeat
TTRX
Sec Filings
- 1/12/26 - Form 8-K
- 1/7/26 - Form 8-K
- 12/12/25 - Form 4
- TTRX's page on the SEC website